Mena Deficiency Delays Tumor Progression and Decreases Metastasis in Mouse Mammary Tumors
Author Information
Author(s): Roussos Evanthia T, Wang Yarong, Wyckoff Jeffrey B, Sellers Rani S, Wang Weigang, Li Jiufeng, Pollard Jeffrey W, Gertler Frank B, Condeelis John S
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Is Mena required for tumor progression and metastasis?
Conclusion
Mena deficiency decreases metastasis by slowing tumor progression and reducing tumor cell invasion and intravasation.
Supporting Evidence
- Mena deficiency increased tumor latency significantly compared to Mena WT and Het mice.
- Mena Null mice had significantly fewer tumors per animal.
- Deficiency of Mena dampened EGF-induced in vivo invasion and motility.
- Mena Null mice showed significantly fewer circulating tumor cells.
- Mena Null mice had significantly fewer lung metastases compared to Mena WT and Het mice.
Takeaway
Mice without Mena take longer to develop tumors and have fewer metastases, which means they live longer.
Methodology
Mena deficient mice were intercrossed with mice expressing the polyoma middle T oncoprotein, and tumor progression was evaluated through various assays.
Limitations
The study primarily focuses on a specific mouse model, which may not fully represent human breast cancer.
Participant Demographics
Mice used in the study were genetically modified to express specific oncogenes.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website